Dr. Tang reviewed colorectal cancer pathology, emphasizing accurate diagnosis, staging, CAP reporting, and biomarker testing (MSI/MMR, HER2) to guide prognosis, adjuvant therapy, and precision care.

Dr. Alese reviewed immunotherapy for MSI-high metastatic CRC. Dual nivolumab/ipilimumab improved outcomes over monotherapy but increased toxicity, supporting biomarker-guided treatment selection.

The panel emphasized dual checkpoint blockade for MSI-high/BRAF-mutant CRC, tissue preservation for genomic testing, accurate pathology reporting, and individualized immunotherapy duration and response assessment.